New Zealand drugs regulator approves use of MDMA to treat severe PTSD
New Zealand's drugs regulator has approved the use of MDMA to treat severe PTSD. The decision follows Australia's approval of psychedelics for similar conditions. The treatment involves controlled clinical sessions with psychotherapy and is not available for home use.
New Zealand has approved MDMA for treating severe PTSD, making it the second country after Australia to do so. The treatment is part of a controlled therapy program.
This approval could offer new treatment options for people with severe PTSD who have not responded to traditional therapies. It reflects growing interest in psychedelic-assisted treatments for mental health.
The decision highlights a constructive approach to mental health care, offering hope and new possibilities for those struggling with trauma. It emphasizes the potential of innovative treatments in improving well-being.
upbeatBytes summarizes in its own words and links to the original publisher — it doesn't host the article.